Unveiling 18 Analyst Insights On Blueprint Medicines
Unveiling 18 Analyst Insights On Blueprint Medicines
公布18位分析师对蓝图药物的见解
Ratings for Blueprint Medicines (NASDAQ:BPMC) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在过去三个月中，18位分析师提供了Blueprint Medicines（纳斯达克股票代码：BPMC）的评级，显示了看涨和看跌的观点。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $111.06, a high estimate of $168.00, and a low estimate of $65.00. Surpassing the previous average price target of $89.40, the current average has increased by 24.23%.
在对12个月目标股价的评估中，分析师公布了对蓝图药品的见解，将平均目标价定为111.06美元，最高估计为168.00美元，低估值为65.00美元。超过了之前的平均目标股价89.40美元，目前的平均价格上涨了24.23％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析师评级：深度分析
The analysis of recent analyst...
对分析师近...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。